VEGF-mediated cross-talk within the neonatal murine thymus

Blood

Volumn 113, Issue 12, 2009, Pages 2723-2731

  Cuddihy, Andrew R ^a   Ge, Shundi ^a   Zhu, Judy ^a   Jang, Julie ^a   Chidgey, Ann ^b   Thurston, Gavin ^c   Boyd, Richard ^b   Crooks, Gay M ^a,d,e  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b MONASH UNIVERSITY   (Australia)

^c REGENERON PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CAPILLARY; CELL COUNT; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DEVELOPMENTAL STAGE; ENDOTHELIUM; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMOCYTE; THYMUS;

EID: 63849242830     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-162040     Document Type: Article

References (42)

1. Anderson G, Jenkinson WE, Jones T, et al. Establishment and functioning of intrathymic micro-environments. Immunol Rev. 2006;209:10-27.
2. van Ewijk W, Hollander G, Terhorst C, Wang B. Stepwise development of thymic microenvironments in vivo is regulated by thymocyte subsets. Development. 2000;127:1583-1591.
3. van Ewijk W, Kawamoto H, Germeraad WT, Katsura Y. Developing thymocytes organize thymic microenvironments. Curr Top Microbiol Immunol. 2000;251:125-132.
4. Haynes BF, Sempowski GD, Wells AF, Hale LP. The human thymus during aging. Immunol Res. 2000;22:253-261.
5. Foss DL, Donskoy E, Goldschneider I. Functional demonstration of intrathymic binding sites and microvascular gates for prothymocytes in irradiated mice. Int Immunol. 2002;14:331-338.
6. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling: in control of vascular function. Nat Rev Mol Cell Biol. 2006;7: 359-371.
7. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439-442.
8. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435-439.
9. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841-844.
10. Gerber HP, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med. 2003;81:20-31.
11. Baffert F, Thurston G, Rochon-Duck M, Le T, Brekken R, McDonald DM. Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ Res. 2004;94:984-992.
12. Gerber HP, Hillan KJ, Ryan AM, et al. VEGF is required for growth and survival in neonatal mice. Development. 1999;126:1149-1159.
13. Thurston G, Wang Q, Baffert F, et al. Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental period. Development. 2005;132:3317-3326.
14. Steinmann GG. Changes in the human thymus during aging. Curr Top Pathol. 1986;75:43-88.
15. Hetzer-Egger C, Schorpp M, Haas-Assenbaum A, Balling R, Peters H, Boehm T. Thymopoiesis requires Pax9 function in thymic epithelial cells. Eur J Immunol. 2002;32:1175-1181.
16. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165:35-52.
17. Gray DH, Chidgey AP, Boyd RL. Analysis of thymic stromal cell populations using flow cytometry. J Immunol Methods. 2002;260:15-28.
18. Prockop S, Petrie HT. Cell migration and the anatomic control of thymocyte precursor differentiation. Semin Immunol. 2000;12:435-444.
19. Su MA, Anderson MS. Aire: an update. Curr Opin Immunol. 2004;16:746-752.
20. Gray DH, Fletcher AL, Hammett M, et al. Unbiased analysis, enrichment and purification of thymic stromal cells. J Immunol Methods. 2008;329:56-66.
21. Thurston G, Baluk P, Hirata A, McDonald DM. Permeability-related changes revealed at endothelial cell borders in inflamed venules by lectin binding. Am J Physiol. 1996;271:H2547-H2562.
22. Raviola E, Karnovsky MJ. Evidence for a blood-thymus barrier using electron-opaque tracers. J Exp Med. 1972;136:466-498.
23. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99:11393-11398.
24. Lammert E, Gu G, McLaughlin M, et al. Role of VEGF-A in vascularization of pancreatic islets. Curr Biol. 2003;13:1070-1074.
25. Tang K, Breen EC, Gerber HP, Ferrara NM, Wagner PD. Capillary regression in vascular endothelial growth factor-deficient skeletal muscle. Physiol Genomics. 2004;18:63-69.
26. Zelzer E, Mamluk R, Ferrara N, Johnson RS, Schipani E, Olsen BR. VEGFA is necessary for chondrocyte survival during bone development. Development. 2004;131:2161-2171.
27. Godfrey DI, Kennedy J, SudaT, Zlotnik A. A developmental pathway involving four phenotypically and functionally distinct subsets of CD3-CD4-CD8- triple-negative adult mouse thymocytes defined by CD44 and CD25 expression. J Immunol. 1993;150:4244-4252.
28. Godfrey DI, Zlotnik A. Control points in early T-cell development. Immunol Today. 1993;14:547-553.
29. Kamba T, Tam BY, Hashizume H, et al. VEGF- dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290:H560-H576.
30. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell. 1993;73:5-8.
31. Mor F, Quintana FJ, Cohen IR. Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol. 2004;172:4618-4623.
32. Raab S, Beck H, Gaumann A, et al. Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thromb Haemost. 2004;91:595-605.
33. Anderson M, Anderson SK, Farr AG. Thymic vasculature: organizer of the medullary epithelial compartment? Int Immunol. 2000;12:1105-1110.
34. Müller SM, Terszowski G, Blum C, et al. Gene targeting of VEGF-A in thymus epithelium disrupts thymus blood vessel architecture. Proc Natl Acad Sci USA. 2005;102:10587-10592.
35. Kiessling R, Wasserman K, Horiguchi S, et al. Tumor-induced immune dysfunction. Cancer Immunol Immunother. 1999;48:353-362.
36. Ohm JE, Gabrilovich DI, Sempowski GD, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003;101:4878-4886.
37. Huang Y, Chen X, Dikov MM, et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood. 2007;110:624-631.
38. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res. 2006;66:1434-1445.
39. Bandeira A, Mota-Santos T, Itohara S, et al. Localization of gamma/delta T cells to the intestinal epithelium is independent of normal microbial colonization. J Exp Med. 1990;172:239-244.
40. Lin T, Matsuzaki G, Yoshida H, et al. CD3-CD8+ intestinal intraepithelial lymphocytes (IEL) and the extrathymic development of IEL. Eur J Immunol. 1994;24:1080-1087.
41. Hayday A. Orchestrated leak provokes a thymus reassessment. Nat Immunol. 2006;7:9-11.
42. Lambolez F, Arcangeli ML, Joret AM, et al. The thymus exports long-lived fully committed T cell precursors that can colonize primary lymphoid organs. Nat Immunol. 2006;7:76-82.